

# Phase I Trial: Quotient Code QSC303299

<b>Submission date</b> 23/01/2026	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 06/02/2026	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/02/2026	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Philip Evans

### Contact details

Mere Way, Ruddington Fields, Ruddington  
Nottingham  
United Kingdom  
NG11 6JS  
+44 (0)3303031000  
recruitment@weneedyou.co.uk

### Type(s)

Scientific, Public

### Contact name

Dr Vicore Study Doctor

### Contact details

Kornhamnstorg 53  
Stockholm  
Sweden  
111 27  
+46 (0)317880560  
karin.eklund.vanderpol@vicorepharma.com

# Additional identifiers

Integrated Research Application System (IRAS)

1013082

## Study information

### Scientific Title

Phase I Trial: Quotient Code QSC303299 [the full scientific title will be published within 30 months after the end of the trial]

### Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

submitted 05/01/2026, London - Harrow REC (Health Research Authority, 2 Redman Place, Stratford, London, E201JQ, United Kingdom; +44 (0)2071048178; harrow.rec@hra.nhs.uk), ref: 26/LO/0005

### Primary study design

Interventional

### Allocation

N/A: single arm study

### Masking

Open (masking not used)

### Control

Uncontrolled

### Assignment

Single

### Purpose

Phase I trial in healthy volunteers

### Study type(s)

### Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## **Interventions**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## **Intervention Type**

Drug

## **Phase**

Phase I

## **Drug/device/biological/vaccine name(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## **Primary outcome(s)**

1. The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. measured using - at -

## **Key secondary outcome(s)**

## **Completion date**

22/05/2026

# **Eligibility**

## **Key inclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## **Healthy volunteers allowed**

Yes

## **Age group**

Mixed

## **Lower age limit**

30 years

## **Upper age limit**

65 years

## **Sex**

Male

## **Total final enrolment**

0

## **Key exclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## **Date of first enrolment**

07/03/2026

## **Date of final enrolment**

22/05/2026

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

#### **Quotient Sciences Limited**

Mere Way

Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

## **Sponsor information**

### **Organisation**

Vicore Pharma (Sweden)

### **ROR**

<https://ror.org/00mkdy143>

## **Funder(s)**

### **Funder type**

### **Funder Name**

Vicore Pharma

# Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**

Not expected to be made available